)
)
)
MindImmune
MindImmune Therapeutics is pioneering a new frontier in Alzheimer’s disease by targeting the immune mechanisms that drive neurodegeneration. Our approach focuses on innate immune cells, which infiltrate the brain and cause synaptic injury and vascular damage—the root causes of cognitive decline in Alzheimer's dementia. MindImmune’s lead antibody, MITI-101, acts peripherally to selectively block the trafficking and activation of these cells, reducing neuroinflammation without suppressing systemic immunity. Backed by leading investors including Pfizer, Dolby, Gates Ventures, and the Alzheimer’s Drug Discovery Foundation, MindImmune will be in first-in-human studies in 2026 with a transformative immunomodulatory therapy designed to halt the progression of Alzheimer’s and restore the brain’s natural resilience to disease.
Address
CambridgeMassachusetts
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)